Meeting
2023 ASCO Gastrointestinal Cancers Symposium
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
Authors
Christopher Hanyoung Lieu
NSABP/NRG Oncology, and University of Colorado Cancer Center, Aurora, CO;
Christopher Hanyoung Lieu , Yan Lin , Scott Kopetz , Samuel A. Jacobs , Peter C. Lucas , Ibrahim Halil Sahin , Dustin A. Deming , Philip Agop Philip , Theodore S. Hong , Yesenia Rojas-Khalil , Jonathan M. Loree , Norman Wolmark , Greg Yothers , Thomas J. George , Arvind Dasari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05174169
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS260)
DOI
10.1200/JCO.2023.41.4_suppl.TPS260
Abstract #
TPS260
Poster Bd #
P2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
First Author: Arvind Dasari
Poster
2024 ASCO Gastrointestinal Cancers Symposium
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
First Author: Christopher Hanyoung Lieu
Poster
2022 ASCO Annual Meeting
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.
First Author: Arvind Dasari
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe